Structured exercise program improves functional capacity and delays relapse in euthyroid patients with Graves' disease

Disability and Rehabilitation

Volumn 34, Issue 18, 2012, Pages 1511-1518

  Cutovic, Milisav ^a,b,c   Konstantinovic, Ljubica ^a,b   Stankovic, Zoran ^c   Vesovic Potic, Vladislava ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Clinic for Rehabilitation Dr Miroslav Zotovic   (Serbia)

^c Institute for Thyroid Gland   (Serbia)

Author keywords

Fatigue; Hyperthyroidism; Medication; Physical activity

Indexed keywords

ANTITHYROID AGENT; THYROID HORMONE;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; EVALUATION; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; KINESIOTHERAPY; MALE; NODULAR GOITER; OXYGEN CONSUMPTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; SERBIA; SOCIOECONOMICS; THYROID FUNCTION TEST; TIME; TREATMENT OUTCOME;

ADULT; ANTITHYROID AGENTS; CASE-CONTROL STUDIES; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GOITER, NODULAR; GRAVES DISEASE; HUMANS; MALE; OXYGEN CONSUMPTION; RECURRENCE; RETROSPECTIVE STUDIES; SERBIA; SOCIOECONOMIC FACTORS; THYROID FUNCTION TESTS; THYROID HORMONES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863938136     PISSN: 09638288     EISSN: 14645165     Source Type: Journal    
DOI: 10.3109/09638288.2012.660599     Document Type: Article

References (49)

1. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group. Clin Endocrinol (Oxf) 1989;31:209-218. (Pubitemid 19196416)
2. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7:369-375. (Pubitemid 27295133)
3. Orgiazzi J, Madec AM. Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease. Thyroid 2002;12: 849-853. (Pubitemid 35332988)
4. Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006;16:295-302.
5. Kashiwai T, Hidaka Y, Takano T, Tatsumi KI, Izumi Y, Shimaoka Y, Tada H, et al. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Endocr J 2003;50:45-49. (Pubitemid 36305846)
6. Kahaly GJ, Nieswandt J, Wagner S, Schlegel J, Mohr-Kahaly S, Hommel G. Ineffective cardiorespiratory function in hyperthyroidism. J Clin Endocrinol Metab 1998;83:4075-4078. (Pubitemid 28513598)
7. Kahaly G, Hellermann J, Mohr-Kahaly S, Treese N. Impaired cardiopulmonary exercise capacity in patients with hyperthyroidism. Chest 1996;109:57-61. (Pubitemid 26017593)
8. Sestoft L, Saltin B. The low physical working capacity of thyrotoxic patients is not normalized by oral antithyroid treatment. Clin Physiol 1988;8:9-15.
9. Kendrick AH, O'Reilly JF, Laszlo G. Lung function and exercise performance in hyperthyroidism before and after treatment. Q J Med 1988;68:615-627.
10. Kimura H, Kawagoe Y, Kaneko N, Fessler HE, Hosoda S. Low efficiency of oxygen utilization during exercise in hyperthyroidism. Chest 1996;110:1264-1270. (Pubitemid 26380483)
11. Irace L, Pergola V, Di Salvo G, Perna B, Tedesco MA, Ricci C, Tuccillo B, Iacono A. Work capacity and oxygen uptake abnormalities in hyperthyroidism. Minerva Cardioangiol 2006;54:355-362. (Pubitemid 44125493)
12. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol 2007;49:71-81. (Pubitemid 46026889)
13. Da Nóbrega AC, Vaisman M, De Araújo CG. Skeletal muscle function and body composition of patients with hyperthyroidism. Med Sci Sports Exerc 1997;29:175-180. (Pubitemid 27113510)
14. Fahrenfort JJ, Wilterdink AM, van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology 2000;25:201-211. (Pubitemid 29525392)
15. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS. The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid 2006;16:375-380.
16. Bousquet-Santos K, Vaisman M, Barreto ND, Cruz-Filho RA, Salvador BA, Frontera WR, Nobrega AC. Resistance training improves muscle function and body composition in patients with hyperthyroidism. Arch Phys Med Rehabil 2006;87:1123-1130. (Pubitemid 44107842)
17. Klecha AJ, Barreiro Arcos ML, Frick L, Genaro AM, Cremaschi G. Immune-endocrine interactions in autoimmune thyroid diseases. Neuroimmunomodulation 2008;15:68-75.
18. Oncu J, Durmaz B, Karapolat H. Short-term effects of aerobic exercise on functional capacity, fatigue, and quality of life in patients with post-polio syndrome. Clin Rehabil 2009;23:155-163.
19. Basmajian JV, Wolf SL. Therapeutic exercise. 5th ed. Baltimore, MA: Williams & Wilkins; 1990.
20. Wilder RP, Jenkins JG, Seto CK, Statuta S. Therapeutic exercise. In: Braddom RL, editor. Physical Medicine & Rehabilitation. 4th ed. Philadephia, PA: Elsevier Saunders; 2011. p. 403-26.
21. Bruce RA. Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res 1971;3:323-332.
22. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381. (Pubitemid 13215050)
23. Portenoy RK. Fatigue. Interactive textbook on clinical symptom research 2011 [cited 2011 Sep 27];Available from: URL: http://painconsortium. nih.gov/symptomresearch/chapter-9/sec6/crps6pg1.htm
24. Weetman AP. Graves' disease. N Engl J Med 2000;343:1236-1248.
25. Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf) 1998;49:451-457. (Pubitemid 28475337)
26. Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J Clin Endocrinol Metab 1998;83:814-818. (Pubitemid 28496452)
27. Martins R, Coelho E Silva M, Pindus D, Cumming S, Teixeira A, Veríssimo M. Effects of strength and aerobic-based training on functional fitness, mood and the relationship between fatness and mood in older adults. J Sports Med Phys Fitness 2011;51:489-496.
28. Watt T, Hegedüs L, Rasmussen AK, Groenvold M, Bonnema SJ, Bjorner JB, Feldt-Rasmussen U. Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. Thyroid 2007;17:647-654. (Pubitemid 47311554)
29. Kaltsas G, Vgontzas A, Chrousos G. Fatigue, endocrinopathies, and metabolic disorders. PM R 2010;2:393-398.
30. Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs 2006;56:617-635. (Pubitemid 44800261)
31. Robinson MM, Hamilton KL, Miller BF. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. J Appl Physiol 2009;107:8-16.
32. Mastorakos G, Pavlatou M, Diamanti-Kandarakis E, Chrousos GP. Exercise and the stress system. Hormones (Athens) 2005;4:73-89.
33. Schott M, Minich WB, Willenberg HS, Papewalis C, Seissler J, Feldkamp J, Bergmann A, et al. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease. Horm Metab Res 2005;37:741-744. (Pubitemid 43028075)
34. Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol 2002;146:173-177. (Pubitemid 34162908)
35. Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment. Horm Metab Res 2002;34:383-388.
36. Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocr J 2007;54:713-720. (Pubitemid 351377748)
37. Okamoto Y, Tanigawa S, Ishikawa K, Hamada N. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 2006;53:467-472. (Pubitemid 44351496)
38. Glinoer D, de Nayer P, Bex M; Belgian Collaborative Study Group on Graves' Disease. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001;144:475-483. (Pubitemid 32487523)
39. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, et al. Antithyroid drugs and Graves' disease-prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999;50:127-132. (Pubitemid 29079378)
40. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 2002;147:583-589. (Pubitemid 35414555)
41. Booth FW, Laye MJ. Lack of adequate appreciation of physical exercise's complexities can pre-empt appropriate design and interpretation in scientific discovery. J Physiol (Lond) 2009;587:5527-5539.
42. Lakier SL. Overtraining, excessive exercise, and altered immunity: is this a T helper-1 versus T helper-2 lymphocyte response? Sports Med 2003;33:347-64.
43. Elenkov IJ, Chrousos GP. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab 1999;10:359-368. (Pubitemid 29496010)
44. Bagnasco M, Bossert I, Pesce G. Stress and autoimmune thyroid diseases. Neuroimmunomodulation 2006;13:309-317. (Pubitemid 47289514)
45. Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects. J Endocrinol Invest 1997;20:452-461. (Pubitemid 27483070)
46. Kraiem Z, Baron E, Kahana L, Sadeh O, Sheinfeld M. Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo to hyper-thyroidism and back to hypothyroidism. Clin Endocrinol (Oxf) 1992;36:211-214.
47. Weetman AP. The immunology of pregnancy. Thyroid 1999;9: 643-646. (Pubitemid 29357904)
48. Kung AW, Jones BM. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy. J Clin Endocrinol Metab 1998;83:514-518. (Pubitemid 28496532)
49. Fukao A, Takamatsu J, Murakami Y, Sakane S, Miyauchi A, Kuma K, Hayashi S, Hanafusa T. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease. Clin Endocrinol (Oxf) 2003;58:550-555. (Pubitemid 36566796)